Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure

OBJECTIVE: The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R-DLBCL) after second-line treatment failure is extremely poor. This study prospectively observed the efficacy and safety of decitabine with a modified cisplatin, cytarabine, and dexamethasone (DHAP) r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Junxia, Wang, Xin, Chen, Fei, Ding, Mengjie, Dong, Meng, Yang, Wanqiu, Yin, Meifeng, Wu, Jingjing, Zhang, Lei, Fu, Xiaorui, Sun, Zhenchang, Li, Ling, Wang, Xinhua, Li, Xin, Guo, Shuangshuang, Zhang, Dianbao, Lu, Xiaohui, Leng, Qing, Zhang, Mingzhi, Zhu, Linan, Zhang, Xudong, Chen, Qingjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253157/
https://www.ncbi.nlm.nih.gov/pubmed/34222013
http://dx.doi.org/10.3389/fonc.2021.687374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253157/
https://www.ncbi.nlm.nih.gov/pubmed/34222013
http://dx.doi.org/10.3389/fonc.2021.687374

Ejemplares similares